Filing Flows › Gossamer Bio (GOSS) › Q1 2026 › vs Q1 2025
Gossamer Bio (GOSS) Q1 2026 vs Q1 2025 (year over year)
Gossamer Bio's revenue rose $7.1M (+71%) from $9.9M in Q1 2025 to $17.0M in Q1 2026.
Gossamer Bio, Q1 2026: revenue $17.0M (+72% year over year), operating margin -264.6%, net loss $46.7M, operating cash flow −$38.7M. The chart draws each line against Q1 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q1 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $17.0M | $9.9M | $7.1M | +71% |
| Net loss | $46.7M | $36.6M | $10.0M | +27% |
| Costs & expenses | $63.6M | $46.7M | $16.9M | +36% |
| Operating costs | $61.8M | $46.7M | $15.1M | +32% |
| Interest & other, net | $1.8M | −$172K | $2.0M | — |
| Research & development | $43.1M | $38.0M | $5.0M | +13% |
| General & admin | $18.7M | $8.7M | $10.1M | +117% |
| Operating cash sources | $46.7M | $36.6M | $10.0M | +27% |
| Depreciation & amortization | $5K | $6K | −$1K | -17% |
| Share-based compensation | $6.3M | $2.4M | $3.9M | +162% |
| Working capital & other | $1.6M | −$5.5M | $7.1M | — |
| Cash used in operations | $38.7M | $39.7M | −$1.0M | -3% |
| Net loss absorbed | $46.7M | $36.6M | $10.0M | +27% |
Questions
How much did Gossamer Bio's revenue grow year over year in Q1 2026?
Gossamer Bio's revenue rose $7.1M (+71%) from $9.9M in Q1 2025 to $17.0M in Q1 2026.